comparemela.com

Nehalj Lakhani News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharmacodynamic effects observed at the 3 mg/kg dose. | May 25, 2023

United statesNorth carolinaLini panditeNehalj lakhaniConor richardsonShattuck labs incExchange commissionChief medical officerDose escalation clinical trialShattuck labsAgonist redirected checkpointGamma deltat cell engagerAnnual reportSafe harborPrivate securities litigation reform actMedia contact

Shattuck Labs to Present Complete Dose-Escalation Data from

- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent.

United statesNorth carolinaConor richardsonNehalj lakhaniLini panditeShattuck labs incExchange commissionChief medical officerDose escalation clinical trialShattuck labsAgonist redirected checkpointGamma deltat cell engagerAnnual reportSafe harborPrivate securities litigation reform actMedia contact

Inhibrx Announces Participation in Upcoming Scientific Conferences

/PRNewswire/ Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare.

United statesBritish columbiaBryan becklundVivek subbiahPharmacometrics acoRobin lewisl jonesSantp chawlaBristol myers squibbNehalj lakhaniSharvari bhagwatPrnewswire inhibrx incSociety for immunotherapy of cancerConnective tissue oncology societyInhibrx incFusion proteinMolecular targeted cytokine

Inhibrx Announces Participation in Upcoming Scientific Conferences

/PRNewswire/ Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare.

United statesBritish columbiaBryan becklundVivek subbiahPharmacometrics acoRobin lewisl jonesSantp chawlaBristol myers squibbNehalj lakhaniSharvari bhagwatPrnewswire inhibrx incSociety for immunotherapy of cancerConnective tissue oncology societyInhibrx incFusion proteinMolecular targeted cytokine

vimarsana © 2020. All Rights Reserved.